# CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM)

> **NCT04933422** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Crimson Biopharm Inc.** · enrollment: 72 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** CM93

## Key facts

- **NCT ID:** NCT04933422
- **Lead sponsor:** Crimson Biopharm Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01
- **Primary completion:** 2029-07
- **Final completion:** 2029-07
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2024-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04933422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04933422, "CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04933422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*